At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 339 enrolled
Drug / intervention
QVA149 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 3 clinical trial evaluating QVA149 and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 339 participants across 53 sites in 10 countries.
Detailed Summary
The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesCanada, France, Hungary, India, Latvia, Lithuania, Romania, South Africa, South Korea, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionDec 2011
TodayJul 2026
First PostedMay 11, 2010
Enrollment StartApr 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.1 years ago
Interventions
QVA149drug
capsules for inhalation, delivered by an SDDPI
Placebodrug
capsules for inhalation, delivered by an SDDPI